Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, MARCH 26, 2026 (GLOBE NEWSWIRE) -- CRINETICS PHARMACEUTICALS, INC. (NASDAQ: CRNX) TODAY ANNOUNCED THE SUBMISSION OF A MARKETING AUTHORIZATION APPLICATION (MAA) TO BRAZIL'S NATIONAL HEALTH SURVEILLANCE AGENCY (ANVISA) FOR PALSONIFY (PALTUSOTINE), THE FIRST ONCE-DAILY, ORAL, SELECTIVELY-TARGETED SOMATOSTATIN RECEPTOR TYPE 2 NONPEPTIDE AGONIST, FOR THE PROPOSED TREATMENT OF ACROMEGALY IN ADULTS. THE SUBMISSION OF OUR MAA FOR PALSONIFY IN BRAZIL REPRESENTS ANOTHER IMPORTANT GLOBAL MILESTONE FOR THIS IMPORTANT THERAPY, SAID SCOTT STRUTHERS, PH.D.

CRINETICS PHARMACEUTICALS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATION IN BRAZIL FOR PALSONIFY (PALTUSOTINE) IN ACROMEGALY

PALSONIFY (PALTUSOTINE) NET PRODUCT REVENUE OF $5.4 MILLION FOR FOURTH-QUARTER 2025, WITH >200 ENROLLMENT FORMS AT THE END OF DECEMBER

CRINETICS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SAN DIEGO, FEB. 05, 2026 (GLOBE NEWSWIRE) -- CRINETICS PHARMACEUTICALS, INC. (NASDAQ: CRNX), TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING TWO UPCOMING INVESTOR CONFERENCES: TD COWEN 46 TH ANNUAL HEALTH CARE CONFERENCE, BOSTON, MA FIRESIDE CHAT ON WEDNESDAY, MARCH 4, 2026 AT 1:50 P.M. EASTERN TIME WEBCAST LINK HERE MANAGEMENT WILL BE AVAILABLE FOR 1X1 MEETINGS WITH INVESTORS ON WEDNESDAY, MARCH 4, 2026 LEERINK ANNUAL GLOBAL HEALTHCARE CONFERENCE, MIAMI, FL MANAGEMENT WILL BE AVAILABLE FOR 1X1 MEETINGS WITH INVESTORS ON WEDNESDAY, MARCH 11, 2026 THE LIVE AND ARCHIVED WEBCAST WILL BE ACCESSIBLE ON THE EVENTS & PRESENTATIONS PAGE IN THE INVESTORS SECTION OF THE CRINETICS' WEBSITE AT WWW.CRINETICS.COM/EVENTS.

CRINETICS PHARMACEUTICALS TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES IN MARCH

SAN DIEGO, JAN. 26, 2026 (GLOBE NEWSWIRE) -- CRINETICS PHARMACEUTICALS, INC. (NASDAQ: CRNX) TODAY ANNOUNCED THAT IT WILL REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 26, 2026 AFTER THE MARKET CLOSES. COMPANY MANAGEMENT WILL HOST A CONFERENCE CALL AT 4:30 P.M. ET TO DISCUSS FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE.

CRINETICS PHARMACEUTICALS TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON FEBRUARY 26, 2026

SAN DIEGO, JAN. 22, 2026 (GLOBE NEWSWIRE) -- CRINETICS PHARMACEUTICALS, INC. (NASDAQ: CRNX) TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE BALANCE-CAH PHASE 2/3 TRIAL EVALUATING INVESTIGATIONAL CANDIDATE ATUMELNANT, A NOVEL, ONCE-DAILY ORAL ADRENOCORTICOTROPIC HORMONE (ACTH) RECEPTOR ANTAGONIST CANDIDATE FOR THE PROPOSED TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) IN CHILDREN AND ADOLESCENTS. BALANCE-CAH IS DESIGNED TO EVALUATE ATUMELNANT FOR THE TREATMENT OF CAH IN PEDIATRIC AGE PATIENTS  FOR WHOM THE LIFELONG BURDEN OF THIS DISEASE BEGINS EARLY, SAID DR. ALAN KRASNER, M.D.

CRINETICS INITIATES PHASE 2/3 PEDIATRIC TRIAL EVALUATING ATUMELNANT IN CONGENITAL ADRENAL HYPERPLASIA (CAH)

SAN DIEGO, JAN. 12, 2026 (GLOBE NEWSWIRE) -- CRINETICS PHARMACEUTICALS, INC. (NASDAQ: CRNX) TODAY ANNOUNCED THAT ON JANUARY 10, 2026, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTION AWARDS TO PURCHASE AN AGGREGATE OF 37,575 SHARES OF ITS COMMON STOCK AND GRANTED AN AGGREGATE OF 25,525 RESTRICTED STOCK UNIT (RSU) AWARDS TO 10 NEW NON-EXECUTIVE EMPLOYEES, IN EACH CASE, UNDER THE CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (THE 2021 INDUCEMENT PLAN). THE STOCK OPTIONS AND RSUS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEES ENTERING INTO EMPLOYMENT WITH CRINETICS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

CRINETICS PHARMACEUTICALS ANNOUNCES JANUARY 2026 INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

SAN DIEGO, JAN. 06, 2026 (GLOBE NEWSWIRE) -- CRINETICS PHARMACEUTICALS, INC. (NASDAQ: CRNX) (CRINETICS), A PHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF NOVEL THERAPEUTICS FOR ENDOCRINE DISEASES AND ENDOCRINE-RELATED TUMORS, ANNOUNCED TODAY THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 7,620,000 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $45.95 PER SHARE. ALL OF THE SHARES TO BE SOLD IN THE OFFERING ARE TO BE SOLD BY CRINETICS. THE GROSS PROCEEDS TO CRINETICS FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $350 MILLION. IN ADDITION, CRINETICS HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 1,143,000 SHARES OF COMMON STOCK. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JANUARY 8, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

CRINETICS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

SAN DIEGO, JAN. 05, 2026 (GLOBE NEWSWIRE) -- CRINETICS PHARMACEUTICALS, INC. (NASDAQ: CRNX) (CRINETICS), A PHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF NOVEL THERAPEUTICS FOR ENDOCRINE DISEASES AND ENDOCRINE-RELATED TUMORS, ANNOUNCED TODAY THAT IT INTENDS TO OFFER AND SELL, SUBJECT TO MARKET AND OTHER CONDITIONS, $350.0 MILLION OF SHARES OF ITS COMMON STOCK IN A PROPOSED UNDERWRITTEN PUBLIC OFFERING. IN ADDITION, CRINETICS INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $52.5 MILLION OF SHARES OF COMMON STOCK. ALL OF THE SHARES TO BE SOLD IN THE PROPOSED OFFERING ARE TO BE SOLD BY CRINETICS. THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

CRINETICS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

STRONG PALSONIFY U.S. LAUNCH EXECUTION RESULTED IN UNAUDITED AND PRELIMINARY NET PRODUCT REVENUE OF >$5 MILLION FOR FOURTH-QUARTER 2025, WITH >200 ENROLLMENT FORMS AT THE END OF DECEMBER ATUMELNANT (80 MG) ACHIEVED A 67% MEAN REDUCTION IN ANDROSTENEDIONE LEVELS WHILE SIMULTANEOUSLY ENABLING 88% OF PARTICIPANTS COMPLETING 12 WEEKS OF TREATMENT TO SUCCESSFULLY REDUCE GLUCOCORTICOID DOSE TO PHYSIOLOGIC REPLACEMENT LEVELS ATUMELNANT'S FAVORABLE BENEFIT/RISK PROFILE WAS MAINTAINED IN COHORT 4 AND OPEN-LABEL EXTENSION OF PHASE 2 CAH STUDY WITH NO HEPATIC TRANSAMINASE ADVERSE EVENTS MANAGEMENT TO HOST INVESTOR CONFERENCE CALL TODAY AT 8:30 AM ET SAN DIEGO, JAN. 05, 2026 (GLOBE NEWSWIRE) -- CRINETICS PHARMACEUTICALS, INC. (NASDAQ: CRNX) TODAY ANNOUNCED PALSONIFY U.S. UNAUDITED AND PRELIMINARY NET PRODUCT REVENUE OF OVER $5 MILLION FOR FOURTH-QUARTER 2025. CRINETICS ALSO ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE FOURTH COHORT OF ITS PHASE 2 CONGENITAL ADRENAL HYPERPLASIA (CAH) STUDY OF INVESTIGATIONAL ATUMELNANT, A NOVEL, ONCE-DAILY ORAL ADRENOCORTICOTROPIC HORMONE (ACTH) RECEPTOR ANTAGONIST CANDIDATE BEING DEVELOPED FOR THE TREATMENT OF CLASSIC CAH AND ACTH-DEPENDENT CUSHING'S SYNDROME.

CRINETICS ANNOUNCES STRONG PALSONIFY LAUNCH EXECUTION AND POSITIVE RESULTS FOR CONCURRENT ANDROSTENEDIONE LOWERING AND GLUCOCORTICOID DOSE REDUCTION IN PHASE 2 TRIAL OF ATUMELNANT FOR CONGENITAL ADRENAL HYPERPLASIA

SAN DIEGO, JAN. 04, 2026 (GLOBE NEWSWIRE) -- CRINETICS PHARMACEUTICALS, INC. (NASDAQ: CRNX), TODAY ANNOUNCED THAT THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST ON MONDAY, JANUARY 5, 2026 AT 8:30 A.M. ET TO PROVIDE AN UPDATE ON PALSONIFY (PALTUSOTINE) COMMERCIALIZATION AND DISCLOSE TOPLINE RESULTS FROM THE FOURTH COHORT OF THE PHASE 2 TRIAL OF ATUMELNANT IN CONGENITAL ADRENAL HYPERPLASIA.

CRINETICS PHARMACEUTICALS TO PROVIDE PALSONIFY BUSINESS UPDATE AND ANNOUNCE TOPLINE RESULTS FROM FOURTH COHORT OF PHASE 2 TRIAL OF ATUMELNANT IN CONGENITAL ADRENAL HYPERPLASIA

Crinetics Pharmaceuticals, Inc.

CRNX

Price

Financial Reports

No items found.

Press Releases

Crinetics Pharmaceuticals, Inc.

CRNX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CRNX